To expand its global influence, Abcam opens a new facility in Boston, USA

To expand its global influence, Abcam opens a new facility in Boston, USA

To expand its global influence, Abcam opens a new facility in Boston, USA to expand its global influence, and Abcam opens a new facility in Boston, USA

• Occupying an area of ​​100,000 square feet, new modern facilities help accelerate the growth of R&D, production and commercial activities

• Occupying an area of ​​100,000 square feet, new modern facilities help accelerate the growth of R&D, production and commercial activities

• The opening of new facilities in many places demonstrates Abcam's determination and investment in expanding its influence in the global life sciences field

• The opening of new facilities in many places demonstrates Abcam's determination and investment in expanding its influence in the global life sciences field

Cambridge, UK, July 13, 2021-Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in the field of life science reagents and tools, recently announced the opening of an important new facility in Boston, Massachusetts, USA
.

The opening of the new facility is a core measure for Abcam to expand its business in the United States.
It aims to strengthen its investment in supporting the global scientific research and biopharmaceutical industry, and will become the company's R&D and business center in the United States
.

Compared with the previous site at Kendall Square in Cambridge, Massachusetts, the capacity of the new Abcam facility has more than doubled and is expected to eventually accommodate approximately 300 employees

"In 2013, Abcam settled in Kendall Square and took the first step in global expansion
.

Since then, the United States has become our largest market

The new facility covers an area of ​​100,000 square feet and will increase the company's flexibility, scale and capabilities in R&D, production, distribution and customer service to meet the growing needs of the life sciences industry
.

Abcam will provide key reagents for research in the entire field of life sciences to support scientific breakthroughs and promote the rapid development of diagnostics, vaccines and potential therapies

Abcam is committed to expanding its influence in the global life sciences field
.

To expand its footprint in the United States, Abcam has been listed on NASDAQ in October 2020 and opened a new cell engineering facility in the San Francisco Bay Area in December 2020

In order to meet the needs of strategic partners and customers for scientific research, treatment and in vitro diagnostic applications, Abcam's Hangzhou factory has been expanded by a third to provide more complete R&D and manufacturing capabilities
.

The factory has brand new automation capabilities and technologies, flexible laboratory configuration and a specially designed logistics center, which will promote the continuous growth of Abcam's high-quality, proven reagent product portfolio